ATE177096T1 - 4-substituierte 1,2,4-triazolderivate - Google Patents

4-substituierte 1,2,4-triazolderivate

Info

Publication number
ATE177096T1
ATE177096T1 AT93305829T AT93305829T ATE177096T1 AT E177096 T1 ATE177096 T1 AT E177096T1 AT 93305829 T AT93305829 T AT 93305829T AT 93305829 T AT93305829 T AT 93305829T AT E177096 T1 ATE177096 T1 AT E177096T1
Authority
AT
Austria
Prior art keywords
substituted
triazole derivatives
receptors
chem
formula
Prior art date
Application number
AT93305829T
Other languages
English (en)
Inventor
Raymond Baker
Victor Giulio Matassa
Austin John Reeve
Francine Sternfeld
Leslie Joseph Street
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929216264A external-priority patent/GB9216264D0/en
Priority claimed from GB929216192A external-priority patent/GB9216192D0/en
Priority claimed from GB929222261A external-priority patent/GB9222261D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE177096T1 publication Critical patent/ATE177096T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT93305829T 1992-07-30 1993-07-23 4-substituierte 1,2,4-triazolderivate ATE177096T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929216264A GB9216264D0 (en) 1992-07-30 1992-07-30 Therapeutic agents
GB929216192A GB9216192D0 (en) 1992-07-30 1992-07-30 Therapeutic agents
GB929222261A GB9222261D0 (en) 1992-10-23 1992-10-23 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE177096T1 true ATE177096T1 (de) 1999-03-15

Family

ID=27266308

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93305829T ATE177096T1 (de) 1992-07-30 1993-07-23 4-substituierte 1,2,4-triazolderivate

Country Status (12)

Country Link
US (1) US5554629A (de)
EP (1) EP0581538B1 (de)
JP (1) JP2599557B2 (de)
CN (1) CN1037101C (de)
AT (1) ATE177096T1 (de)
AU (1) AU664102B2 (de)
CA (1) CA2101219A1 (de)
DE (1) DE69323667T2 (de)
ES (1) ES2127789T3 (de)
IL (1) IL106445A (de)
MX (1) MX9304595A (de)
WO (1) WO1994003446A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402016D0 (en) * 1994-02-02 1994-03-30 Merck Sharp & Dohme Therapeutic agents
GB9402011D0 (en) * 1994-02-02 1994-03-30 Merck Sharp & Dohme Therapeutic agents
GB9410031D0 (en) * 1994-05-19 1994-07-06 Merck Sharp & Dohme Therapeutic agents
US5552402A (en) * 1994-05-19 1996-09-03 Merck, Sharp & Dohme Ltd. Five-membered heteroaromatic compounds as 5-HT receptor agonists
US5854268A (en) * 1994-08-02 1998-12-29 Merck Sharp & Dohme, Ltd. Azetidine, pyrrolidine and piperidine derivatives
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CZ288897A3 (cs) * 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
CA2234166A1 (en) * 1995-10-10 1997-04-17 Patric James Hahn N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
US5998438A (en) * 1996-11-26 1999-12-07 Allelix Biopharmaceuticals, Inc. 5-cyclo indole compounds
DE69819903T2 (de) 1997-08-09 2004-11-11 Smithkline Beecham P.L.C., Brentford Bicyclische verbindungen als liganden der 5-ht1 rezeptoren
FR2767827A1 (fr) * 1997-09-03 1999-02-26 Adir Nouveaux derives de l'indole et de l'indazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
DK1068198T3 (da) * 1998-03-09 2003-09-22 Lundbeck & Co As H 5-Heteroarylsubstituerede indoler
US7375219B2 (en) 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
AR060451A1 (es) 2006-04-13 2008-06-18 Neuraxon Inc Compuestos de indol 1,5 y 3,6-sustituidos con actividad inhibitoria de nos
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
WO2010084507A2 (en) * 2008-07-15 2010-07-29 Sun Pharmaceutical Industries Ltd. Process for the preparation of n-methyl-2-[3-(1-methyl-4-piperidyl)-1h-indol-5-yl]-ethanesulfonamide and its acid addition salts

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3475437A (en) * 1964-06-05 1969-10-28 Boehringer Sohn Ingelheim 3-tertiary amino lower alkylpseudoindoles
GB1237008A (en) * 1968-12-18 1971-06-30 Pfizer Ltd Novel indoline derivatives
US3686213A (en) * 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
DE2520816C3 (de) * 1975-05-09 1979-02-15 Bayer Ag, 5090 Leverkusen Methinfarbstoffe
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
NL8103764A (nl) * 1980-08-12 1982-03-01 Glaxo Group Ltd Heterocyclische verbindingen, werkwijze ter bereiding daarvan, alsmede farmaceutische preparaten die deze verbindingen als actieve component bevatten.
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4453001A (en) * 1982-02-22 1984-06-05 Sandoz, Inc. Isoxazolyl indolamines as intermediates
JPS58150576A (ja) * 1982-03-03 1983-09-07 Sumitomo Chem Co Ltd 新規な１，２，４−オキサジアゾ−ル誘導体
US4692531A (en) * 1984-06-22 1987-09-08 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
US5225431A (en) * 1987-10-23 1993-07-06 Burroughs Wellcome Co. Therapeutic substituted indole compounds and compositions thereof
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
AU646871B2 (en) * 1990-06-07 1994-03-10 Astrazeneca Uk Limited Therapeutic heterocyclic compounds
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i

Also Published As

Publication number Publication date
CA2101219A1 (en) 1994-01-31
IL106445A (en) 1998-01-04
CN1037101C (zh) 1998-01-21
MX9304595A (es) 1994-02-28
JPH06184139A (ja) 1994-07-05
WO1994003446A1 (en) 1994-02-17
AU4215593A (en) 1994-02-03
US5554629A (en) 1996-09-10
AU664102B2 (en) 1995-11-02
EP0581538B1 (de) 1999-03-03
IL106445A0 (en) 1993-11-15
DE69323667T2 (de) 1999-09-30
CN1089262A (zh) 1994-07-13
ES2127789T3 (es) 1999-05-01
DE69323667D1 (de) 1999-04-08
JP2599557B2 (ja) 1997-04-09
EP0581538A1 (de) 1994-02-02

Similar Documents

Publication Publication Date Title
ATE177096T1 (de) 4-substituierte 1,2,4-triazolderivate
DK0957099T3 (da) Heterocykliske carboxamider
DK0418845T3 (da) Pyrazolderivater, fremgangsmåder til fremstilling deraf og farmaceutisk præparat omfattende samme
HU9600834D0 (en) Quinazoline derivatives
FI941378A (fi) Bentsimidatsoliyhdisteitä, niiden käyttö ja valmistus
DK0776324T3 (da) Endothelin-antagonister
ATE226574T1 (de) 4,6-diarylpyrimidin-derivate und deren salze
DK391289A (da) Indolderivater
ATE210649T1 (de) Arylacrylamidderivate als 5ht1 agoniste oder antagoniste
DK0952154T3 (da) N-acyl- og N-aroylaralkylamider
DE69810960D1 (de) 2-phenoxyanilin-derivate
DK0573221T3 (da) Sulfatsaltet af en substitueret triazol, farmaceutiske præparater deraf og deres anvendelse i terapi
DE69617226D1 (de) Piperidinderivate.
FI952420A0 (fi) Glukopyranosidibentsotiofeenit
ATE165083T1 (de) N-arylalkylphenylacetamidderivate
PT855398E (pt) Derivados sasquiterpeno tendo actividade antiviral
ATE146481T1 (de) Epoxysuccinamidsäurederivat
FI914219A (fi) 3-(1h-indazol-3-yl)-4-pyridinaminer, foerfarande och mellanprodukter foer deras framstaellning och deras anvaendning som laekemedel.
MX9205408A (es) Metodo para tratar hipertension.
FI894125A (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisen 3-piperidinyyli-indatsolin valmistamiseksi
DE69932441D1 (de) Cyanoiminochinoxalin-derivate
ES2141134T3 (es) Derivados de carbamoil pirrolidona para el tratamiento de la depresion y de los trastornos cerebrovasculares.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties